Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) - Total Liabilities

Latest as of September 2025: $2.78 Billion USD

Based on the latest financial reports, Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) has total liabilities worth $2.78 Billion USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Amneal Pharmaceuticals, Inc. Class A Com cash flow conversion to assess how effectively this company generates cash.

Amneal Pharmaceuticals, Inc. Class A Common Stock - Total Liabilities Trend (2015–2024)

This chart illustrates how Amneal Pharmaceuticals, Inc. Class A Common Stock's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Amneal Pharmaceuticals, Inc. Class A Com to evaluate the company's liquid asset resilience ratio.

Amneal Pharmaceuticals, Inc. Class A Common Stock Competitors by Total Liabilities

The table below lists competitors of Amneal Pharmaceuticals, Inc. Class A Common Stock ranked by their total liabilities.

Company	Country	Total Liabilities
Olav Thon Eien OL:OLT	Norway	Nkr32.70 Billion
Maximus Inc NYSE:MMS	USA	$2.49 Billion
GZ Port SHG:601228	China	CN¥28.08 Billion
Hainan Mining Co Ltd SHG:601969	China	CN¥6.57 Billion
Glanbia PLC IR:GL9	Ireland	€1.85 Billion
ELF Beauty Inc NYSE:ELF	USA	$1.16 Billion
Zhejiang Huahai Pharmaceutical Co Ltd SHG:600521	China	CN¥11.55 Billion
Cactus Inc NYSE:WHD	USA	$471.36 Million

Liability Composition Analysis (2015–2024)

This chart breaks down Amneal Pharmaceuticals, Inc. Class A Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Amneal Pharmaceuticals, Inc. Class A Com stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.13	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	3.39	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.77	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Amneal Pharmaceuticals, Inc. Class A Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Amneal Pharmaceuticals, Inc. Class A Common Stock (2015–2024)

The table below shows the annual total liabilities of Amneal Pharmaceuticals, Inc. Class A Common Stock from 2015 to 2024.

Year	Total Liabilities	Change
2024-12-31	$3.55 Billion	+2.71%
2023-12-31	$3.45 Billion	-3.84%
2022-12-31	$3.59 Billion	+0.50%
2021-12-31	$3.57 Billion	-2.41%
2020-12-31	$3.66 Billion	+10.30%
2019-12-31	$3.32 Billion	-3.97%
2018-12-31	$3.46 Billion	+101.25%
2017-12-31	$1.72 Billion	+23.14%
2016-12-31	$1.39 Billion	+16.14%
2015-12-31	$1.20 Billion	--

About Amneal Pharmaceuticals, Inc. Class A Common Stock

NYSE:AMRX USA Drug Manufacturers - Specialty & Generic

Market Cap

$3.83 Billion

Market Cap Rank

#4441 Global

#1446 in USA

Share Price

$12.18

Change (1 day)

+2.01%

52-Week Range

$7.16 - $12.52

All Time High

$44.76